Table 3.
Comparison of FA outcomes among the 3 groups.
| Group | Case number | Ipsilateral FA value | Contralateral FA value | Change value | Rate of change value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Week 0 | Week 3 | Week 0 | Week 3 | Ipsilateral FA change | Contralateral FA change | Ipsilateral rate | Contralateral rate | ||
| Four-channel | 6 | 0.155 ± 0.087 | 0.321 ± 0.172a | 0.585 ± 0.058 | 0.588 ± 0.068 | 0.166 ± 0.111 | 0.002 ± 0.038 | 0.073 ± 0.017 | 0.044 ± 0.034a |
| Dual-channel | 6 | 0.186 ± 0.076 | 0.333 ± 0.164a | 0.600 ± 0.1 | 0.590 ± 0.124 | 0.147 ± 0.091 | −(0.009 ± 0.106) | 0.069 ± 0.011 | 0.043 ± 0.021a |
| Placebo | 6 | 0.185 ± 0.12 | 0.217 ± 0.135 | 0.558 ± 0.123 | 0.562 ± 0.129 | 0.032 ± 0.052bc | 0.065 ± 0.118 | 0.061 ± 0.023 | 0.060 ± 0.025bc |
Value: mean ± SD; change value: FA values of week 3 minus those of week 0; rate of change value: (ipsilateral FA − contralateral FA)/ipsilateral FA∗100%. ap < 0.05 indicates significant difference when compared with week 0 within groups. bp < 0.05 indicates significant difference when compared with the four-channel group. cp < 0.05 indicates significant difference when compared with the dual-channel group.